Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

Stock Information for Mustang Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Mustang Bio Inc.

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi(TM) (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights 
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.